Format

Send to

Choose Destination
Nat Rev Immunol. 2012 Jul 25;12(8):592-605. doi: 10.1038/nri3251.

Recent progress in mucosal vaccine development: potential and limitations.

Author information

1
Center for Mucosal Immunobiology and Vaccines (MIVAC), Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Sweden. nils.lycke@microbio.gu.se

Abstract

Most pathogens access the body through the mucosal membranes. Therefore, effective vaccines that protect at these sites are much needed. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently launched. This is partly due to problems with developing safe and effective mucosal adjuvants. In the past decade, however, the successful development of live attenuated mucosal vaccines against influenza virus and rotavirus infections has boosted interest in this field, and great expectations for new mucosal vaccines lie ahead. Here, I discuss the expanding knowledge and strategies used in the development of mucosal vaccines.

PMID:
22828912
DOI:
10.1038/nri3251
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center